Your shopping cart is currently empty

PD-L1-IN-3 (Compound 4a) functions as an inhibitor of the PD-1/PD-L1 axis, with an IC50 value of 4.97 nM for PD-L1 inhibition and an EC50 value of 2.70 μM for Jurkat T cell modulation. It antagonizes the PD-1/PD-L1 interaction by binding to the PD-L1 dimer, obstructing PD-1 signaling. This compound is utilized in research pertaining to lung cancer and melanoma [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $90 | In Stock | In Stock | |
| 5 mg | $222 | In Stock | In Stock | |
| 10 mg | $355 | In Stock | In Stock | |
| 25 mg | $689 | In Stock | In Stock | |
| 50 mg | $1,090 | In Stock | In Stock | |
| 100 mg | $1,730 | In Stock | In Stock |
| Description | PD-L1-IN-3 (Compound 4a) functions as an inhibitor of the PD-1/PD-L1 axis, with an IC50 value of 4.97 nM for PD-L1 inhibition and an EC50 value of 2.70 μM for Jurkat T cell modulation. It antagonizes the PD-1/PD-L1 interaction by binding to the PD-L1 dimer, obstructing PD-1 signaling. This compound is utilized in research pertaining to lung cancer and melanoma [1]. |
| In vitro | PD-L1-IN-3 (Compound 4a) disrupts the PD-1 and PD-L1 interaction at concentrations of 0.01 to 100 μM over 40 minutes, enhancing TCR-mediated activation of Jurkat cells [1]. Additionally, PD-L1-IN-3 demonstrates increased uptake in PD-L1-positive H358 tumors, proportional to PD-L1 expression levels [1]. |
| In vivo | In PD-L1+/− (H358 and ES2) tumors, PD-L1-IN-3 (0.01-100 μM; incubation) was observed to exhibit 40-55% higher uptake in PD-L1+ H358 tumors compared to wild-type counterparts. However, it failed to distinguish between wild-type and knockout ES2 samples[1]. |
| Molecular Weight | 373.85 |
| Formula | C19H15ClFN2OS |
| Cas No. | 2953044-29-4 |
| Smiles | [Cl].N#CC1=C(OCC2=CC=C(C=C2)CN)SC=C1C=3C=CC(F)=CC3 |
| Relative Density. | no data available |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (267.49 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.